South San Francisco, CA, January 30, 2025 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has awarded nearly ...

BEHIND THE WALLS of San Quentin Rehabilitation Center, incarcerated individuals are writing powerful narratives to share with ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.

( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults.

Our goal is to relieve pain and help patients regain function without surgery. We create personalized care plans to address each ...

The first comprehensive guidelines dedicated to minimizing infections in patients undergoing surgeries and procedures ...

Our editors also may be in touch with follow-up questions. Cannabidiol (CBD) may offer numerous health benefits, including pain relief and anxiety relief, without the intoxicatingly psychoactive ...

KANSAS CITY, Mo. — One of Kansas City's largest developments in 2025 is well underway in the Northland — the Google data center campus. But what is a data center and why are so many building ...